Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Lenvatinib in Children With Primary CNS Tumors
NCT05081180Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Dec 2021
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of avelumab and lenvatinib in central nervous system tumor, sponsored by EMD Serono. Primary endpoints: Number of Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater Than or Equal to (>=) 3 Treatment-emergent Adverse Event (TEAEs) up to 857 days, Number of Participants With Dose Limiting Toxicities at Day 28 and 1 more. Started Dec 2021; status: terminated.
02
Drugs
avelumablenvatinib
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT05081180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081180.